

Goutham Narla

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9143338/goutham-narla-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

4,351
citations

39
h-index

64
g-index

147
ext. papers

5,119
ext. citations

9.8
avg, IF

4.98
L-index

#	Paper	IF	Citations
112	Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.. <i>JCO Oncology Practice</i> , 2022 , OP2100693	2.3	
111	Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. <i>Case Reports in Oncology</i> , 2021 , 14, 224-231	1	1
110	Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. <i>Scientific Reports</i> , 2021 , 11, 10252	4.9	2
109	Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. <i>Clinical Science</i> , 2021 , 135, 1545-1556	6.5	2
108	CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. <i>Cancer Research</i> , 2021 , 81, 4319-4331	10.1	4
107	PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3 β Mediated c-Myc and Pim-1 Proteasomal Degradation. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 676-690	6.1	1
106	Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm. <i>Clinical Science</i> , 2021 , 135, 2085-2097	6.5	1
105	Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma.. <i>Cancer Research</i> , 2021 ,	10.1	2
104	Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis. <i>Cancer Discovery</i> , 2020 , 10, 765-767	24.4	1
103	A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors. <i>Cancer Research</i> , 2020 , 80, 3305-3318	10.1	11
102	Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. <i>Cancer Cell</i> , 2020 , 38, 129-143.e7	24.3	22
101	Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr on PP2Ac. <i>Cell Reports</i> , 2020 , 30, 3164-3170.e3	10.6	5
100	Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. <i>Brain Communications</i> , 2020 , 2, fcaa002	4.5	7
99	Selective PP2A Enhancement through Biased Heterotrimer Stabilization. <i>Cell</i> , 2020 , 181, 688-701.e16	56.2	49
98	Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 15-17	2.2	
97	Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. <i>Journal of Clinical Investigation</i> , 2020 , 130, 231-246	15.9	16
96	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex. <i>PLoS Biology</i> , 2020 , 18, e3000803	9.7	8

95	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. <i>PLoS ONE</i> , 2020 , 15, e0240169	3.7	2
94	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. <i>Journal of Biological Chemistry</i> , 2020 , 295, 757-770	5.4	18
93	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. <i>Journal of Biological Chemistry</i> , 2020 , 295, 757-770	5.4	18
92	Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. <i>Cancer Letters</i> , 2020 , 493, 80-90	9.9	3
91	Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. <i>Oncogene</i> , 2020 , 39, 703-717	9.2	16
90	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex 2020 , 18, e3000803		
89	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex 2020 , 18, e3000803		
88	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex 2020 , 18, e3000803		
87	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex 2020 , 18, e3000803		
86	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex 2020 , 18, e3000803		
85	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex 2020 , 18, e3000803		
84	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies 2020 , 15, e0240169		
83	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies 2020 , 15, e0240169		
82	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies 2020 , 15, e0240169		
81	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies 2020 , 15, e0240169		
80	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019 , 9, 1538-1555	24.4	35
79	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. <i>Molecular Cancer Research</i> , 2019 , 17, 1815-1827	6.6	24
78	The Highly Recurrent PP2A A β Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. <i>Cancer Research</i> , 2019 , 79, 4242-4257	10.1	19

77	Lulling the Cancer Cell into an Eternal Sleep. <i>Cancer Research</i> , 2019 , 79, 1756-1757	10.1	
76	Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. <i>Scientific Reports</i> , 2019 , 9, 6428	4.9	11
75	Protein phosphatase 2A A β regulates A β protein expression and stability. <i>Journal of Biological Chemistry</i> , 2019 , 294, 5923-5934	5.4	4
74	Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia". <i>Science Translational Medicine</i> , 2019 , 11,	17.5	4
73	Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45). <i>Journal of Biological Chemistry</i> , 2019 , 294, 17043-17059	5.4	7
72	Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. <i>JCI Insight</i> , 2019 , 4,	9.9	25
71	RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1641-1653	15.9	17
70	PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation. <i>Blood</i> , 2019 , 134, 1276-1276 ¹	2.2	1
69	Targeting PP2A in cancer: Combination therapies. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019 , 1866, 51-63	4.9	48
68	Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2019 , 79, 209-219	10.1	32
67	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 2065-2080	10.1	41
66	The impact of phosphatases on proliferative and survival signaling in cancer. <i>Cellular and Molecular Life Sciences</i> , 2018 , 75, 2695-2718	10.3	20
65	Therapeutic targeting of PP2A. <i>International Journal of Biochemistry and Cell Biology</i> , 2018 , 96, 182-193	5.6	82
64	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	72
63	Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas. <i>Blood</i> , 2018 , 132, 2649-2649 ^{2,3}	3.3	2649
62	Specificity of research antibodies: "trust is good, validation is better". <i>Human Pathology</i> , 2018 , 72, 199-201	9.7	3
61	Sprague Dawley -Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 2481-2489	6.1	13
60	Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. <i>Proteomics</i> , 2017 , 17, 1700214	4.8	14

59	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2081-2090	15.9	106
58	The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination. <i>PLoS Biology</i> , 2016 , 14, e1002467	9.7	21
57	All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. <i>FEBS Journal</i> , 2016 , 283, 1004-24	5.7	175
56	Reengineered tricyclic anti-cancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 6528-34	3.4	38
55	Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 7487	3.4	2
54	Krüppel-like factor 6 regulates mitochondrial function in the kidney. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1347-61	15.9	50
53	Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF- κ B, and cell-cycle progression in non-small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2203-14	6.1	48
52	Kruppel-like transcription factor 6 regulates inflammatory macrophage polarization. <i>Journal of Biological Chemistry</i> , 2014 , 289, 10318-10329	5.4	91
51	microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. <i>Nature Communications</i> , 2014 , 5, 2977	17.4	183
50	IKK β negatively regulates ASC-dependent inflammasome activation. <i>Nature Communications</i> , 2014 , 5, 4977	17.4	70
49	Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17995-8000	11.5	45
48	Bisphosphonates inactivate human EGFRs to exert antitumor actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17989-94	11.5	47
47	Enhanced antitumor activity of erlotinib in combination with quinacrine in EGFR WT and L858R/T790M mutant NSCLC. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22153-e22153	2.2	
46	KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. <i>Science Translational Medicine</i> , 2013 , 5, 169ra12	17.5	58
45	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012 , 56, 1361-70	11.2	30
44	Kruppel-like factor 15 (KLF15) is a key regulator of podocyte differentiation. <i>Journal of Biological Chemistry</i> , 2012 , 287, 19122-35	5.4	73
43	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. <i>Journal of Clinical Investigation</i> , 2012 , 122, 2637-51	15.9	65
42	Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 406-16	4	54

41	Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011 , 54, 522-31	11.2	34
40	Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 1167-70	5.9	12
39	Lung adenocarcinoma: lessons in translation from bench to bedside. <i>Mount Sinai Journal of Medicine</i> , 2010 , 77, 597-605		30
38	Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. <i>FEBS Letters</i> , 2010 , 584, 1006-10	3.8	18
37	KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. <i>Cancer Research</i> , 2009 , 69, 4733-41	10.1	36
36	TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction. <i>Biochemical Journal</i> , 2009 , 419, 485-95	3.8	35
35	Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. <i>International Journal of Cancer</i> , 2009 , 125, 774-82	7.5	77
34	Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. <i>Mount Sinai Journal of Medicine</i> , 2009 , 76, 557-66		12
33	The role of KLF6 and its splice variants in cancer therapy. <i>Drug Resistance Updates</i> , 2009 , 12, 1-7	23.2	90
32	Functional role of the KLF6 tumour suppressor gene in gastric cancer. <i>European Journal of Cancer</i> , 2009 , 45, 666-76	7.5	38
31	Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. <i>Lung Cancer</i> , 2009 , 66, 292-7	5.9	18
30	Kruppel-like Factors and the Liver 2009 , 141-150		2
29	Kruppel-like Factors KLF6 and KLF6-SV1 in the Diagnosis and Treatment of Cancer 2009 , 223-244		
28	Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. <i>Gastroenterology</i> , 2008 , 134, 1521-31	13.3	79
27	Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2008 , 44, 1895-903	7.5	33
26	The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2008 , 135, 282-291.e1	13.3	149
25	A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. <i>Cancer Research</i> , 2008 , 68, 965-70	10.1	56
24	Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. <i>Endocrinology</i> , 2008 , 149, 1890-7	4.8	18

23	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , 2008 , 118, 2711-21	15.9	89
22	Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. <i>International Journal of Cancer</i> , 2007 , 121, 1390-5	7.5	63
21	KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2007 , 121, 1976-83	7.5	30
20	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007 , 46, 645-54	13.4	67
19	Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. <i>Carcinogenesis</i> , 2006 , 27, 216-24	4.6	16
18	Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. <i>Clinical Cancer Research</i> , 2006 , 12, 3730-9	12.9	89
17	KLF6 degradation after apoptotic DNA damage. <i>FEBS Letters</i> , 2006 , 580, 6981-6	3.8	26
16	KLF6 is one transcription factor involved in regulating acid ceramidase gene expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005 , 1732, 82-7		14
15	Reply:. <i>Hepatology</i> , 2005 , 41, 682-683	11.2	10
14	Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. <i>Cancer Research</i> , 2005 , 65, 5761-8	10.1	133
13	Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. <i>Journal of Biological Chemistry</i> , 2005 , 280, 26941-52	5.4	131
12	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. <i>Cancer Research</i> , 2005 , 65, 1213-22	10.1	182
11	Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. <i>Cancer Research</i> , 2005 , 65, 9216-25	10.1	50
10	Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. <i>Endocrinology</i> , 2004 , 145, 3769-77	4.8	49
9	Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. <i>Cancer Research</i> , 2004 , 64, 3885-91	10.1	137
8	Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. <i>Oncogene</i> , 2004 , 23, 5077-83	9.2	75
7	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004 , 40, 1047-52	11.2	130
6	Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. <i>Gastroenterology</i> , 2004 , 126, 1090-103	13.3	151

5	Ribosomal protein S19 expression during erythroid differentiation. <i>Blood</i> , 2003 , 101, 318-24	2.2	51
4	Krüppel cripples prostate cancer: KLF6 progress and prospects. <i>American Journal of Pathology</i> , 2003 , 162, 1047-52	5.8	39
3	Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. <i>American Journal of Human Genetics</i> , 2003 , 73, 957-66	11	147
2	The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. <i>Nature Genetics</i> , 1995 , 9, 424-31	36.3	112
1	Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma		1